Biomx INC 8-K filings

BiomX has been granted an extension until November 23, 2025, to regain compliance with NYSE American listing standards.

BiomX Inc. stockholders approved an amended incentive plan and an increase in authorized common stock shares at their annual meeting on July 9, 2024.

BiomX Inc. has finalized its acquisition of Adaptive Phage Therapeutics, adding two Phase 2 assets to its pipeline and expanding its focus on phage-based therapies.

BiomX Inc. has received a notice from the NYSE American for failing to meet continued listing standards due to a stockholders equity deficiency, requiring the company to submit a compliance plan by June 22, 2024.

BiomX Inc. has increased its board size to eight members, appointed a new director, and amended its bylaws to remove the requirement for an odd number of directors.

BiomX acquired Adaptive Phage Therapeutics, secured $50 million in funding, and is advancing its clinical-stage phage therapy programs for cystic fibrosis and diabetic foot osteomyelitis.

BiomX Inc. has finalized committee assignments for its recently appointed directors, effective immediately.

BiomX Inc. finalized its acquisition of Adaptive Phage Therapeutics, issuing warrants to a landlord and appointing new board members, while also filing a Certificate of Designation for Series X preferred stock.

BiomX Inc. is set to acquire Adaptive Phage Therapeutics, enhancing its phage therapy pipeline and securing $50 million in private financing.